Acrotech Biopharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Acrotech Biopharma sits in the top decile of US sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count).
Acrotech Biopharma: 24 sponsored US clinical trials, 2 recruiting.
Acrotech Biopharma sponsors 24 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 21 completed. 3 of these trials are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral T-Cell Lymphoma, with 2 trials.
Top-decile sponsor footprint
Acrotech Biopharma ranks in the top decile of sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
21 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
24 total, page 1 of 1
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
NCT06072131
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
NCT07036133
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
NCT05608343
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
NCT05571943
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
NCT04184869
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
NCT02680795
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
NCT02679131
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
NCT02594267
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
NCT02106650
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
NCT01839097
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
NCT01660633
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
NCT01310244
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
NCT01222780
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
NCT01118624
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
NCT01134341
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
NCT01110733
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
NCT00925782
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
NCT00722553
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
NCT00554827
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
NCT00481871
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
NCT00364923
Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
NCT00145041
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00144963
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
NCT01851551
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 6 |
| Phase 3 | 3 |
What is open in the Acrotech Biopharma pipeline
2 recruiting of 24 indexed (8% open); 21 completed (88%).
Phase mix: 3 late (III/IV) vs 20 early (I/II) (early-phase heavy).
Top condition: Peripheral T-Cell Lymphoma (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Acrotech Biopharma: open-pipeline peers nationwide
Peers matched on 24 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Acrotech Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 24 trials (± recruiting share)
- Agenus · 24 trials · 0% recruiting
- Akebia Therapeutics · 24 trials · 4% recruiting
- Blueprint Medicines Corporation · 24 trials · 25% recruiting
- Concert Pharmaceuticals · 24 trials · 0% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Atlanta VA Medical Center · 8% recruiting · 12 trials
- Beacon Therapeutics · 8% recruiting · 12 trials
- Boston VA Research Institute · 8% recruiting · 12 trials
- Centrexion Therapeutics · 8% recruiting · 12 trials
Related
What to do with this Acrotech Biopharma page
24 registered trials is a research-attention snapshot, not an endorsement of Acrotech Biopharma or any single study.
- 2 of Acrotech Biopharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Peripheral T-Cell Lymphoma is the condition Acrotech Biopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral T-Cell Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Acrotech Biopharma pipeline card: 24 registered trials from official public datasets.Report a data error.